| Literature DB >> 31286828 |
Camila Bonin Pinto1,2,3, Leon Morales-Quezada1,3, Polyana Vulcano de Toledo Piza1,3,4, Dian Zeng1,3, Faddi Ghassan Saleh Vélez1,3,5, Isadora Santos Ferreira1,3, Pedro Henrique Lucena1,3, Dante Duarte1,3, Fernanda Lopes1,3, Mirret M El-Hagrassy1,3, Luiz Vicente Rizzo3, Erica C Camargo1,6, David J Lin1,6, Nicole Mazwi1,3,6, Qing Mei Wang1,6,4,7, Randie Black-Schaffer1,3,6, Felipe Fregni1,3,6.
Abstract
Background. Although recent evidence has shown a new role of fluoxetine in motor rehabilitation, results are mixed. We conducted a randomized clinical trial to evaluate whether combining repetitive transcranial magnetic stimulation (rTMS) with fluoxetine increases upper limb motor function in stroke. Methods. Twenty-seven hemiparetic patients within 2 years of ischemic stroke were randomized into 3 groups: Combined (active rTMS + fluoxetine), Fluoxetine (sham rTMS + fluoxetine), or Placebo (sham rTMS + placebo fluoxetine). Participants received 18 sessions of 1-Hz rTMS in the unaffected primary motor cortex and 90 days of fluoxetine (20 mg/d). Motor function was assessed using Jebsen-Taylor Hand Function (JTHF) and Fugl-Meyer Assessment (FMA) scales. Corticospinal excitability was assessed with TMS. Results. After adjusting for time since stroke, there was significantly greater improvement in JTHF in the combined rTMS + fluoxetine group (mean improvement: -214.33 seconds) than in the placebo (-177.98 seconds, P = 0.005) and fluoxetine (-50.16 seconds, P < 0.001) groups. The fluoxetine group had less improvement than placebo on both scales (respectively, JTHF: -50.16 vs -117.98 seconds, P = 0.038; and FMA: 6.72 vs 15.55 points, P = 0.039), suggesting that fluoxetine possibly had detrimental effects. The unaffected hemisphere showed decreased intracortical inhibition in the combined and fluoxetine groups, and increased intracortical facilitation in the fluoxetine group. This facilitation was negatively correlated with motor function improvement (FMA, r2 = -0.398, P = 0.0395). Conclusion. Combined fluoxetine and rTMS treatment leads to better motor function in stroke than fluoxetine alone and placebo. Moreover, fluoxetine leads to smaller improvements than placebo, and fluoxetine's effects on intracortical facilitation suggest a potential diffuse mechanism that may hinder beneficial plasticity on motor recovery.Entities:
Keywords: cortical excitability; fluoxetine; motor recovery; recovery of function; stroke; transcranial magnetic stimulation
Mesh:
Substances:
Year: 2019 PMID: 31286828 PMCID: PMC6688938 DOI: 10.1177/1545968319860483
Source DB: PubMed Journal: Neurorehabil Neural Repair ISSN: 1545-9683 Impact factor: 3.919